Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

about

Arginine deprivation by arginine deiminase of Streptococcus pyogenes controls primary glioblastoma growth in vitro and in vivo.Mechanism of temozolomide-induced antitumour effects on glioma cells.

P2860

Q36214996-A926BDF7-1553-4CA6-A499-92B38D0D8A06 Q39044642-A907C855-3F47-4470-BF8B-E0847D5FC3CC

P2860

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

Item

http://www.wikidata.org/entity/Q39142115

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Cilengitide response in ultra- ...... relation to molecular markers.

@en

Cilengitide response in ultra- ...... relation to molecular markers.

@nl

type

Item

label

Cilengitide response in ultra- ...... relation to molecular markers.

@en

Cilengitide response in ultra- ...... relation to molecular markers.

@nl

prefLabel

Cilengitide response in ultra- ...... relation to molecular markers.

@en

Cilengitide response in ultra- ...... relation to molecular markers.

@nl

P1476

Cilengitide response in ultra- ...... relation to molecular markers.

@en

P2093

Björn Schneider

http://www.w3.org/2001/XMLSchema#string

Carl F Classen

http://www.w3.org/2001/XMLSchema#string

Christina S Mullins

http://www.w3.org/2001/XMLSchema#string

Julia Schubert

http://www.w3.org/2001/XMLSchema#string

Michael Linnebacher

http://www.w3.org/2001/XMLSchema#string

P2860

Integrin ligands at a glance

αV integrins in angiogenesis and cancer

Integrins: bidirectional, allosteric signaling machines

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.

Antiangiogenic strategies and agents in clinical trials.

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.

A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306)

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.

P2888

s00432-013-1457-6

P304

1425-1431

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00432-013-1457-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

139

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

237084775

http://www.w3.org/2001/XMLSchema#string

P698

23749036

http://www.w3.org/2001/XMLSchema#string

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

about

P2860

P2860

Cilengitide response in ultra-low passage glioblastoma cell lines: relation to molecular markers.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P698